The goal of this Roundtable is to understand and address the role of new and emerging LDL-C lowering therapies in patients with ASCVD and high-risk primary prevention as well as those with ...

LDL cholesterol is the primary target of therapy to lower cardiovascular risk. Statins are medications of first ... times the upper limit of normal, statin use can be discontinued and the ...

Moreover, innovative treatments need to address non-LDL-C residual risk (which may be marked by high triglycerides, low HDL-C concentrations ... Pitavastatin is a novel statin that induces plaque ...

NEXLETOL is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for indicated patients. NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers ...

and the 2022 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. The information ...

Alzheimer's disease, a devastating neurodegenerative condition that impacts millions globally, may have found an unexpected ...

Correspondence to Dr Frank L J Visseren, Department of Vascular Medicine ... if LDL-C and other risk factors levels were low. Conclusion The individual estimated lifetime benefit from PCSK9 inhibition ...

The trial evaluated the efficacy of obicetrapib, an oral, non-statin cholesterol-lowering medication, in patients with cardiovascular disease and high low-density lipoprotein cholesterol (LDL-C) ...

Low levels of HDL and high levels of LDL cholesterol are both important predictors of cardiovascular disease. LDL cholesterol levels are effectively lowered by statin therapy, significantly ...